Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study

Agnese Comelli1*, Giulia Viero2, Greta Bettini3, Alessandro Nobili3, Mauro Tettamanti3, Alessia Antonella Galbussera3, Antonio Muscatello1, Marco Mantero2,4, Ciro Canetta3, Filippo Martinelli Boneschi2,6, Andrea Arighi6, Paolo Brambilla2,7, Maurizio Vecchi2,8, Pietro Lampertico2,9, Paolo Bonfanti10, Marco Contoli11, Francesco Blasi2,4, Andrea Gori1,2 and Alessandra Bandera1,2 on behalf of the COVID-19 Network

Objective: Our knowledge on the long-term consequences of COVID-19 is still scarce despite the clinical relevance of persisting syndrome. The aim of this study was to analyze patient-reported outcomes, including assessment by specific questionnaires of health impairment and symptoms.

Methods: This is a prospective, observational and multicenter cohort study coordinated by Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milano and Istituto di Ricerche Farmacologiche Mario Negri IRCCS including eight hospitals located in North and Central Italy. A telephone interview to assess rehospitalization, access to health care resources, general health status subjective evaluation, and symptoms was performed at 12 months after the discharge in patients admitted to hospital because of COVID-19 from February 2020 to the end of May 2020.

Results: Among the 776 patients discharged alive, 44 (5.7%) died, 456 subjects (58.8%) completed the questionnaire and 276 (35.6%) were not reachable or refused to join the telephone interview. The mean age of the study population was 59.4 years (SD 14.1), 69.8% of individuals needed oxygen support during hospitalization and 10.4% were admitted to ICU. Overall, 91.7% of participants reported at least one symptom/sequela at 12 months. Exertional dyspnea (71.7%), fatigue (54.6%), and gastrointestinal symptoms (32.8%) were the most reported ones. Health issues after discharge including hospitalization or access to emergency room were described by 19.4% of subjects. Female and presence of comorbidities were independent predictors.
Comelli et al. Long COVID-19 1 Year After Hospitalization

of health impairment and presence of $\geq 2$ symptoms/sequelae after 12 months from hospitalization for COVID-19.

Conclusions: Patient-reported symptoms and sequelae, principally dyspnea and fatigue, are found in most individuals even 12 months from COVID-19 hospitalization. Long-term follow-up based on patient-centered outcome can contribute to plan tailored interventions.

Keywords: long COVID-19, SARS-CoV-2, long-term sequelae, COVID-19, dyspnea

INTRODUCTION

Since the first documented case of pneumonia related to SARS-CoV-2 in December 2019, progresses have been made on management of COVID-19.

However, researchers have focused mainly on the acute phase, attention has lately been shifting to post-COVID-19 signs and symptoms and, as a consequence, there is still very limited information on the sequelae of COVID-19 (1). The exact nature and prevalence of persistent symptoms after SARS-CoV-2 infection are not known, but an increasing number of studies are reporting a high incidence of sequelae during the convalescence months, defined as “long-COVID-19”, which recently obtained a formal definition by WHO (2).

Long-COVID-19 sequelae were reported by several studies and range from cough, dyspnea, fatigue, chest pain, migraine but also neurocognitive symptoms such as depression, anxiety, and insomnia (3, 4). During early COVID-19 convalescence, these clinical sequelae seem to be related to gender, age, BMI, and clinical severity during hospitalization (5, 6).

Unfortunately, robust data are lacking in terms of duration of this syndrome, risk factors, long term differences among patients with severe COVID-19 and individuals who experienced only mild or no symptoms, best methods to follow those patients and potential treatment.

With that in mind, it is likely that patients recovering from COVID-19 might need support for a wide range of complications (7) and evidence shows that follow-up programs and rehabilitation services should be developed to address the impact of “long haulers” (8).

Studies published on long COVID-19 until now showed a high degree of heterogeneity. In particular they considered very different follow-up lengths, mainly from 3 to 6 months, discordant inclusion criteria with many cohorts involving both hospitalized and non-hospitalized patients, diverse signs and symptoms investigated and a different approach in patient assessment ranging from hospital visit, dedicated mobile phone applications and telephone interviews to collect self-reported symptoms (4–6, 8–18).

Here, we present a prospective study designed to assess a large class of patient-reported symptoms and sequelae in a homogenous cohort of hospitalized patients after 12 months of follow up.

![Flow chart of patients with COVID-19 discharged between the pandemic beginning and May 31st, 2020.](image-url)
METHODS

Study Design and Participants
This is a prospective, observational and multicenter cohort study supported by Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano and Istituto di Ricerche Farmacologiche Mario Negri IRCCS including eight hospitals located in North and Central Italy.

All consecutive adults with a positive RT-PCR result for SARS-CoV-2 admitted to eight hospitals located in North and Central Italy were enrolled in the COVID-19 Network cohort. Patients aged <18 years and pregnant women were excluded.

Data collected included age, sex, comorbidities, signs and symptoms of COVID-19 at admission, hospitalization length, ICU admission, acute complications during hospital stay, and destination after discharge. Acute complications during hospitalization included Acute Respiratory Distress Syndrome (ARDS), infections, Acute Kidney Injury (AKI), cardiologic events, metabolic, hepatic/gastrointestinal, haematologic or neurologic disorders, thrombosis, or acute ischemic-hemorrhagic events. A severity scale was used to stratify patients considering the oxygen support needed: grade 0 (oxygen support not required), grade 1 (oxygen through Venturi mask), and grade 2 [oxygen through High Flow Nasal Cannula (HFNC), CPAP or non-invasive ventilation].

Outcomes
The follow up was proposed by telephone interview to all COVID-19 Network patients who were discharged alive between the beginning of the pandemic (last week of February 2020) and the 31st May 2020.

Four outcomes were assessed: (i) significant medical problems defined as need of hospitalization or emergency room (ER) access and cardio-neuro-vascular events after the discharge; (ii) patients’ subjective perception of general health; (iii) symptoms (ageusia, anosmia, cough, dyspnea at rest, episodes of anxiety, exertional dyspnea (measured by the modified British Medical Research Council (mMRC) dyspnea scale (19), fatigue, gastrointestinal symptoms, headache, loss of appetite, myalgia, limitations on daily life activities, memory problems, sleep disorders); (iv) presence of a group of sequelae which include dyspnea at rest and exertional dyspnea, myalgia, and limitations on daily life activities that we arbitrarily grouped as “disabling sequelae” considering their impact on general health status and daily life.

Patient’s subjective assessments was recorded on a 0–10 scale to evaluate the generic health status and capacity to appreciate smells and taste (0 = very poor, 10 = very good).

For the remaining symptoms and signs a 0–10 scale was employed where 0 = absence of the symptom and 10 = maximum intensity. A subjective score ≥5 was considered as presence of symptom.

For example, we asked patients direct question like: “how would you score your state of health from 0 to 10 where 0 = absence of the symptom and 10 = maximum subjective intensity?"

Outcomes were assessed at 12 months after discharge from COVID-19 hospitalization. Participants were asked to report their symptoms as present or not.

| TABLE 1 | Characteristics of patients hospitalized with COVID-19 and discharged alive who consented to follow up interview. |
| --- | --- |
| Total, N | 456 |
| Female, N (%) | 168 (36.8%) |
| Age, mean (SD) | 59.4 (14.1) |
| Age, range (N, %) | 18–44 62 (13.6%) 45–64 225 (49.3%) ≥65 169 (37.1%) |
| Ethnicity, N (%) | Caucasian 377 (87.7%) Other 53 (12.3%) |
| Comorbidities, N (%) | Respiratory diseases 52 (11.7%) Cardiovascular diseases 188 (42.2%) Nephropathies 16 (3.4%) GI diseases and hepatopathies 37 (8.3%) Rheumatological diseases 10 (2.3%) Metabolic diseases 81 (18.2%) Neurologic diseases 20 (4.5%) Cancer 16 (3.6%) SOT and HSCT 5 (1.1%) |
| Number of comorbidities, N (%) | 0 176 (40.4%) 1–2 197 (45.2%) ≥3 63 (14.5%) |
| Symptoms at COVID-19 onset, N (%) | Respiratory symptoms 364 (80.4%) Systemic symptoms* 412 (90.4%) Neurologic symptoms 64 (14.4%) GI symptoms 85 (18.8%) |
| Number of symptoms at COVID-19 onset, median (IQR) | 3 (2–4) |
| Hospitalization length, median (IQR) | 12 (6–21) |
| ICU admission, N (%) | <14 days 242 (53.1%) ≥14 days 214 (46.9%) |
| Destination after discharge, N (%) | Home 378 (84.4%) Rehab facility/Long-term care 70 (15.6%) |
| Complications during hospital stay, N (%) | 250 (55.0%) |
| Severity scale, N (%) | 1 (H, no oxygen required) 136 (30.2%) 2 (H, O₂ max Venturi Mask) 224 (49.7%) 3 (H, HFNC or CPAP or NIV) 91 (20.2%) |
current symptoms, i.e., those present in the previous 14 days, except for gastrointestinal symptoms whose presence had to be reported during the 12 months period (from discharge to administration of the questionnaire).

Patients who died during the 12 months from hospital discharge were identified through Regional Health Care System informatic tool.

Questionnaires were administered via telephone interviews run by a trained medical investigator. If the subject was unreachable at first call, three attempts were made.

Answers to the questionnaire were filled into the REDCap data capture tool.

The study protocol was approved by the institutional review board (Ethics Committee of Milano Area 2, number 556) and informed consent was provided by all study participants. All procedures were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statistics

The study population was described with means and standard deviations for continuous variables, and with frequencies and percentages for categorical variables. Characteristics of patients with and without interview were compared using Pearson’s chi-squared for categorical variables and t-test for the continuous ones.

Logistic regressions were fitted to find which baseline and COVID-19 characteristic were associated with presence of the following outcomes at 12 months: health status deterioration, severe medical problems, and high frequency of sequelae. We first calculated different models corrected for age, sex, number of comorbidities, and ethnicity. Subsequently all significant ($p < 0.05$) variables were included in corrected models.

Statistical analyses were performed using Stata v.15.1 (Stata Corp, College Station, TX). In this study, we followed the strengthening the Reporting of observational studies in epidemiology (STROBE) guidelines (see Supplementary Material).

RESULTS

A total of 776 patients admitted to hospital because of COVID-19 and discharged alive from February 28 to May 31, 2020 were included in the analysis. Forty-four subjects (5.7%) died during the 12 months after discharge and 276 (35.6%) subjects were unreachable or refused to join the telephone interview. Four hundred and fifty-six individuals completed the questionnaire (58.8%; Figure 1).

Table 1 summarizes the demographic and clinical characteristics of the study population. Patients were mainly of Caucasian origin (87.7%) and male (63.2%). Mean age was 59.4 years (SD 14.1).

Nearly 60% of patients had at least one comorbidity with the 14.4% suffering from more than three comorbidities. Cardiovascular diseases were the most common health problem present (42.2%).

The median length of hospital stay was 12.0 (IQR 6.0–21.0) days and 46 subjects (10.4%) were admitted to the intensive care unit (ICU).

One hundred and thirty-six (30.2%) participants did not require oxygen support during their hospital stay, 224 (49.7%) required it through nasal cannula or Venturi mask and 91 (20.2%) needed high-flow oxygen support through HFNC, CPAP or non-invasive ventilation (Table 1).

We compared participants who joined the follow-up to those who were unreachable or refused to join the survey. In the latter
group mean age was significantly higher (64 years vs. 59 among the participants, \( p < 0.001 \)). Patients who were unreachable or refused telephone interview were more frequently discharged to rehabilitation centers/nursing homes (\( p < 0.001 \)), had a higher number of comorbidities (\( p = 0.074 \)) and, specifically, had more neurologic (\( p = 0.039 \)) or metabolic (\( p = 0.018 \)) comorbidities, and suffered more from acute complications during the hospitalization in COVID-19 unit (\( p = 0.044 \)) (Supplementary Table S1).

**Patient-Reported Symptoms and Sequelae at 12 Months**

Overall, 91.7% of patients reported at least one persisting symptom/sequela 12 months after hospital discharge and 69.6% reported two or more symptoms.

Respiratory problems were the most reported symptoms/sequelae with 71.7% of participants suffering from exertional dyspnea (score \( \geq 1 \) in mMRC scale), while 12.5% of participants reported dyspnea at rest (Figure 2).

Other most common symptoms reported at 12 months were fatigue (54.6%), gastrointestinal symptoms (altered bowel habits and bloating) (32.8%), sleep disorders (32.4%), anxiety (23.2%), and myalgias (22.3%; Table 2).

When comparing participants with 0–1 persisting symptoms at 12 months to those who reported \( \geq 2 \) symptoms, predictors of \( \geq 2 \) symptoms reported were: female sex (aOR = 2.44, 95% CI: 1.45–4.1, and \( p = 0.001 \)) and 1–2 comorbidities (aOR = 2.24, 95% CI: 1.32–3.8, and \( p = 0.009 \)), while older age (\( \geq 65 \) years old) showed a protective role (aOR = 0.43, 95% CI: 0.19–0.99, and \( p < 0.027 \); Figure 3).

When all significant (\( p < 0.05 \)) variables were included in a general multivariable model, female sex, older age, and the presence of 1–2 comorbidities at baseline were confirmed as independent predictors of \( \geq 2 \) symptoms (Supplementary Table S2).

About 81% patients reported at least one disabling sequelae (dyspnea at rest, exertional dyspnea, myalgia, and limitations on daily life activities) and 30.1% reported two or more.

Female sex (aOR = 2.62, 95% CI: 1.64–4.17, and \( p < 0.001 \)), 1–2 comorbidities at baseline (aOR = 1.19, 95% CI: 1.12–3.27, and \( p = 0.048 \)), number of symptoms in the acute phase (aOR = 1.2, 95% CI: 1.02–1.41, and \( p = 0.031 \)), presence of respiratory symptoms (aOR = 2.05, 95% CI: 1.07–3.93, and \( p = 0.031 \)) and neurologic symptoms (aOR = 1.98, 95% CI: 1.04–3.76, and \( p = 0.038 \)) during COVID-19 hospitalization were associated to the presence of two or more disabling sequelae (Supplementary Table S3).

**General Health Status at 12 Months**

Self-perception of general health 12 months after COVID-19 discharge was poor (a score \( < 5 \)) in 2.4% of patients whereas 31.7% reported an excellent health status (a score \( \geq 9 \)) (Figure 4).

When comparing post- to pre-COVID19 scores of self-perception of general health, 55.5% of participants reported a lower score after COVID-19, while 44.5% described a stable or improved score (38.3% stable health status, 6.2% an improved health condition).

### TABLE 2 | Persistent symptoms and sequelae investigated among patients with COVID-19, discharged alive and who agreed to follow up interview (\( n = 456 \)).

| Symptom Type | N (%) | Value |
|--------------|-------|-------|
| General health status after COVID-19, N (%) | | |
| \(<5\) | 11 (2.42%) | |
| \(5–6\) | 65 (14.32%) | |
| \(7–8\) | 234 (51.54%) | |
| \(9–10\) | 144 (31.72%) | |
| Severe medical issues after COVID-19, N (%) | | |
| ER admission | 47 (10.35%) | |
| Hospitalization | 30 (6.61%) | |
| - Respiratory problems | 5 (1.10%) | |
| - Neurologic problems | 1 (0.22%) | |
| - Psychiatric problem | 0 | |
| - GI problems | 1 (0.22%) | |
| - Hepatologic problems | 2 (0.44%) | |
| - Cardiovascular problems | 17 (3.72%) | |
| Other | 15 (3.30%) | |
| Other | 15 (3.30%) | |
| Respiratory symptoms, N (%) | | |
| Dyspnea at rest (\(\geq 5\)) | | |
| Exertional dyspnea | | |
| - mMRC 0 | 128 (28.32%) | |
| - mMRC \(\geq 1\) | 324 (71.68%) | |
| Cough | 73 (16.08%) | |
| GI symptoms, N (%) | | |
| Altered gastrointestinal function (altered bowel habits and bloating) | 148 (32.75%) | |
| Other symptoms, N (%) | | |
| Sniff disorder (\(\geq 5\)) | 18 (3.96%) | |
| Taste disorder (\(\geq 5\)) | 13 (2.86%) | |
| Memory disorder (\(\geq 5\)) | 15 (3.47%) | |
| Fatigue | 230 (54.65%) | |
| Headache | 73 (17.38%) | |
| Sleep difficulties | 147 (32.38%) | |
| Decreased appetite | 34 (7.49%) | |
| Limitations to daily activities (limitations to daily activities \(+\) troubled walking) | 69 (16.35%) | |
| Anxiety (\(\geq 5\)) | 104 (23.16%) | |
| Myalgia | 94 (22.27%) | |

Predictors significantly associated to health impairment were female sex (aOR = 2.08, 95% CI: 1.36–3.18, and \( p = 0.001 \)), cardiovascular comorbidities (aOR = 1.85, 95% CI: 1.05–3.24, and \( p = 0.032 \)), and a longer length of hospital stay (Figure 4).

When all significant (\( p < 0.05 \)) variables were included in a general multivariable model, female sex, and hospitalization length remained as independent predictors of health impairment (Supplementary Table S4).

**Significant Medical Problems After Hospital Discharge**

Overall, 19.4% of participants accessed to health care resources during the 12 months after discharge, including: access to ER (10.6% of patients) and need of hospitalization (6.6% of patients; Table 2).
A longer hospital stay during COVID-19 was associated to a higher incidence of significant medical problem after discharge (adjusted aOR = 1.02, 95% CI: 1.003–1.05, and p = 0.023) (Supplementary Table S5). No other characteristic was related to presence of significant problem during 12 months after hospital discharge.

DISCUSSION

In the present study, we showed that ∼90% of individuals admitted to hospital for COVID-19 still presents self-reported symptoms 12 months after discharge being respiratory symptoms and fatigue the most common reported sequelae.

To our knowledge, this is one of the largest multicentric and prospective studies on long COVID-19 among patients hospitalized with COVID-19 and followed up systematically after 12 months.

In comparison with other studies, we recorded a very high rate of sequelae. Notably, many of these studies included a large proportion of non-hospitalized patients (4, 6) and others excluded patients who required intubation/mechanical ventilation or reported comorbidities at baseline (11).

In our study, the high rate of COVID-19 patient-reported symptoms/sequelae can be also explained by the large number of areas covered by the survey: beyond respiratory symptoms and fatigue, patients frequently reported systemic symptoms, sleep disorders, and psychological distress.

Moreover, the approach based on subjects’ perception we used in this study (telephone interview) and the psychological...
effects of the subsequent and concurrent COVID-19 waves could overestimate the presence of persisting symptoms.

As confirmed by other authors, female sex, and comorbidities were strongly related to long-COVID19 syndrome (4–6, 9, 12, 14, 17, 20, 21).

In order to explain the correlation between female sex and long COVID-19, physiological and social factors have been reported as possible drivers (15, 22). Nevertheless, Wu et al. (11) demonstrated that female sex strongly predicts impaired DLCO (diffusion lung capacity for carbon monoxide) at 12 months after discharge, suggesting that a physio-pathological process might be present. Moreover, Seeßle et al. proposes a potential role of autoimmunity disorders as co-factor in long COVID incidence and, if proven, it could partially explain the female predisposition to such a syndrome.

Interestingly, and in sharp contrast with other studies (6, 9, 23), age seems to have a protective role on self-perception of symptoms/sequelae after 12 months. A UK study on long COVID-19 supported this finding, indeed they reported that the prevalence of self-reported sequelae was greatest in people aged 35–69 years (24). It is possible that younger patients dedicate more attention to possible signs of health impairment (22), they are probably more reliable in the telephone interview and, at present, we cannot exclude that the development of long COVID could be secondary to an altered immune response possibly more pronounced in younger individuals.

In our study, more than 50% of patients referred health impairment after COVID-19. Interestingly, those subjects frequently present cardiovascular comorbidities. Therefore, the pre-existence of a cardiovascular disease might be a predictive
factor of a harder rehabilitation probably because of the effect of SARS-CoV-2 pneumonia on the cardiovascular system (25).

Interestingly, our findings show that the severity of acute COVID-19 (ICU stay, severity scale, and complications during hospitalization) does not have a significant impact on long COVID-19.

Thus far, available findings on long COVID-19 incidence do not differ so much between non-hospitalized subjects and hospitalized ones (6, 9, 17, 18). This data, shared by several groups, deserves attention and could be an interesting starting point for further analysis.

As experienced in many other contexts during the present pandemic, most studies dealing with post-COVID-19 have employed surveys by telephone call or mobile Apps (5, 6, 9, 16–18, 26, 27).

In our study, nearly 50% refused the survey or were not reachable but, unfortunately, we do not know the correct proportion of the two sub-population. Those people were fragile patients, older, and/or hosted in long-term rehabilitation centers.

In some studies, subjects with expected communication impairment were excluded (12, 26) allowing authors to be more selective and, consequently, the percentage of reported COVID-19 sequelae resulted lower. In conclusion, our findings are probably more representative of a younger and healthier population while fragile subjects are underrepresented in our study and in all similar ones. Targeted studies are needed.

Our study has several limitations. First, the absence of a control group and of an intermediate follow up time point makes it difficult to highlight improving or worsening trend.

Second, by focusing on hospitalized patients, symptoms reported after 12 months could be attributable to either COVID-19 or by the hospitalization, making it difficult to identify the direct consequence of COVID-19. Third, telephone interviews did not permit any objective measures of patient symptoms or signs but, conversely, self-reported symptoms could represent a selection tool to identify those patients who may benefit from an outpatient assessment.

By contrast, some strengths are evident. This is one of the few available prospective studies on COVID-19 follow-up which evaluated health status of a large and homogenous cohort of previously hospitalized patients at 12 months after discharge in Lombardy, one of the most affected regions in Europe during the first wave.

The questionnaire, within the limits of its structure, allowed to investigate many areas of one's health status.

Moreover, all data were collected prospectively, both during acute COVID-19 and during follow up in order to avoid possible bias during retrospective collection of hospitalization documents.

To conclude, in this study we highlighted the existence of a long COVID-19 pandemic lasting 12 months after hospitalization and emphasize the need to implement public-health strategies to manage this condition. Future studies are likely to clarify the chronic nature of long-COVID-19 and, consequently, the need for large-scale economic investments in terms of public health and social policies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Milano Area 2, number 556. The patients/participants provided their written informed consent to participate in this study.

COVID-19 NETWORK” WORKING GROUP

Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico. Silvano Bosari, Luigia Scudeller, Giuliana Fuseti, Laura Rusconi, and Silvia Dell’Orto: Scientific Direction. Daniele Prati, Luca Valenti, Silvia Giovannelli, Maria Manunta, Giuseppe Lamorte, and Francesca Ferrari: Department of Transfusion Medicine and Hematology (Biobank). Andrea Gori, Alessandra Bandera, Antonio Muscatello, Davide Mangioni, Laura Alagna, Giorgio Bozzi, Andrea Lombardi, Riccardo Ungerari, Giuseppe Ancona, Marco Musa, Bianca Veronica Mariani, Matteo Bolis, Nathalie Iannotti, Serena Ludovisi, Agnese Comelli, Giulia Renisi, Simona Biscarini, Valeria Castelli, Emanuele Palomba, Marco Fava, Valeria Fortina, Carlo Alberto Peri, Paola Saltini, Giulia Vero, Teresa Itri, Valentina Ferroni, Valeria Pastore, Roberta Massafra, Arianna Liparoti, Toussaint Muheberman, Alessandro Giommi, Rosaria Bianco, Rafaela Montalvao De Azevedo, and Grazia Eliana Chitani: Infectious Diseases Unit. Flora Peyvandi, Roberta Gualtierotti, Barbara Ferrari, Raffaella Rossio, Nadia Boasi, Erica Pagliaro, Costanza Massimo, Michele De Caro, and Andrea Giachi: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa. Nicola Montano, Barbara Vigone, Chiara Bellocci, Angelica Carandina, Elisa Fiorelli, Valerie Melli, and Eleonora Tobaldini: UOC Internal Medicine, Immunology and Allergology. Francesco Blasi, Stefano Aliberti, Maura Spotti, Leonardo Terranova, Sofia Misuraca, Alice D’Adda, Silvia Della Fiore, Marta DiPasquale, Marco Mantero, Martina Contarini, Margherita Ori, Letizia Morlacchi, Valeria Rossetti, Andrea Gramigna, Maria Pappalettera, Mirta Cavallini, and Agata Buscemi: Respiratory Unit and Cystic Fibrosis Adult Center. Marco Vicenzi, Irena Rota, Giorgio Costantino, Monica Solbati, Ludovico Furlan, Marta Mancarella, Giulia Colombo, Giorgio Colombo, Alice Fanin, Christian Folli, and Silvia Accordion: Acute Internal Medicine. Diletta Maira, Cinzia Maria Hu, Irene Motta, and Natalia Scaramellini: Rare Diseases Center. Anna Ludovica Fracanzani, Rosa Lombardi, and Annalisa Cespiati: General Medicine and Metabolic Diseases. Matteo Cesari, Tiziano Lucchi, Marco Proietti, Laura Calcaterra, Clara Mandelli, Carlotta Coppola, and Arturo Cerizza: Geriatric Unit. Antonio Maria Pesenti, Giacomo Grasselli, and Alessandro Galazzi: Intensive Care Unit. Elisa Colombo, Filippo Cantù, Valentina Tombola, and Francesca Gallo: Psychiatry Unit. Alessandro Nobili, Mauro Tettamanti,
REFERENCES

1. Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered patients with COVID-19. Lancet. (2021) 397:173–5. doi: 10.1016/S0140-6736(21)00398-8

2. World Health Organization. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. Geneva: World Health Organization (2021). Available online at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1

3. The Lancet. Facing up to long COVID. Lancet. (2020) 396:1861. doi: 10.1016/S0140-6736(20)32662-3

4. Seefeld J, Waterboer T, Hippchens T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. (2021) ciab611. doi: 10.1093/cid/ciab611

5. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. (2021) 27:89–95. doi: 10.1016/j.cmi.2020.09.023

6. Boscollo-Rizzo P, Guida F, Polsel J, Marcuzzo AV, Capriotti V, D’Alessandro A, et al. Sequele in adulti a 12 mesi dopo malattia da COVID-19. Int Forum Allergy Rhinol. (2021) 11:1685–8. doi: 10.1002/ir.22832

7. Tansey CM. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med. (2007) 167:1312. doi: 10.1001/archinte.167.12.1312

8. Halpin SJ, McVor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med ViroL. (2021) 93:1013–22. doi: 10.1002/jmv.26368

9. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. (2021) 27:626–31. doi: 10.1038/s41591-021-01292-y

10. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. (2021) 8:416–27. doi: 10.1016/S2215-0366(21)00084-5

11. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. (2021) 9:747–54. doi: 10.1016/S2213-2600(21)00174-0

12. Huang C, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. (2021) 397:220–32. doi: 10.1016/S0140-6736(20)32656-8

13. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603. doi: 10.1001/jama.2020.12603

14. Ghosn J, Piroth L, Epaulard O, Le Turnier P, Mentré F, Bachelet D, et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. (2021) 27:1041.e1–e4. doi: 10.1016/j.cmi.2021.03.012

15. Göertz YMI, Van Herck M, Delbressine JM, Vae AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. (2020) 6:00542–2020. doi: 10.1183/23120541.00542-2020

16. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequele in adulti a 6 mesi dopo COVID-19 infection. JAMA Netw. Open. (2021) 4:e210830. doi: 10.1001/jamanetworkopen.2021.0830

17. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. (2021) 27:1507–13. doi: 10.1016/j.cmi.2021.05.033

18. Righi E, Mirandola M, Mazzaferrri F, Razzaboni E, Zaffagnini A, Erbogasto A, et al. Long-term patient-centred follow-up in a prospective cohort of patients with COVID-19. Infect Dis Ther. (2021) 10:1579–90. doi: 10.1007/s40121-021-00461-3

19. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. (1988) 95:580–6. doi: 10.1378/chest.93.5.580

20. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morrice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. (2021) 199:113–9. doi: 10.1007/s00408-021-00423-z

21. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mule G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. (2021) 293. doi: 10.1016/j.cmi.2021.11.002
22. Bardel A, Wallander M-A, Wallman T, Rosengren A, Johansson S, Eriksson H, et al. Age and sex related self-reported symptoms in a general population across 30 years: patterns of reporting and secular trend. PLoS One. (2019) 14:e0211532. doi: 10.1371/journal.pone.0211532

23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

24. Ayoubkhani D, Bosworth M. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) infection in the UK. Office for National Statistics Bulletin (2021). p. 1–16. Available online at: https://www ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/4november2021 (accessed December 10, 2021) (cited November 21, 2021).

25. Puntmann VO, Carej ML, Wieters I, Fatim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020) 5:1265. doi: 10.1001/jamacardio.2020.3557

26. Weerahandi H, Hochman KA, Simon E, Blaum C, Chodosh J, Duan E, et al. Post-discharge health status and symptoms in patients with severe COVID-19. J Gen Intern Med. (2021) 36:738–45. doi: 10.1007/s11606-020-06338-4

27. Romero-Duarte Á, Rivera-Izquierdo M, Guerrero-Fernández de Alba I, Pérez-Contreras M, Fernández-Martínez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. (2021) 19:129. doi: 10.1186/s12916-021-02003-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.